Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks if immunotherapy drug durvalumab helps lung cancer patients after standard treatment

NCT ID NCT07309211

Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the safety and effectiveness of the immunotherapy drug durvalumab in 25 people with limited-stage small cell lung cancer who have already had chemotherapy and radiation. The drug is given as a follow-up treatment to try to keep the cancer from coming back. Researchers will track side effects and how long patients live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy drug)
What this could lead to
If successful, this could show that durvalumab is safe and effective after sequential chemoradiotherapy, offering a new treatment option for limited-stage small cell lung cancer.
What could go wrong
This is a small, retrospective study with only 25 patients, so results may not apply broadly. The drug may cause serious side effects, and the study does not compare durvalumab to a placebo or other treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will retrospectively collect cases of eligible LS-SCLC patients who received sCRT and have not progressed followed by receiving Durvalumab as consolidation therapy. The retrospective collection of cases for initiating the administration of Durvalumab spans from December 9, 2019, to April 10, 2025. Retrospective analysis of each case should meet all of the inclusion criteria and exclusion criteria for this study. Under no circumstances can there be exceptions to this rule.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥18 at initial diagnosis; 2. Histological or cytological evidence of LS-SCLC (Stage I-III); Stage I-II must be medically inoperable; 3. Received chemotherapy sequential with radiotherapy as first-line treatment and no progression, followed by receiving Durvalumab at least 1 dose as consolidation treatment until progression, unacceptable toxicity or for a maximum of 24 months; 4. Start Durvalumab treatment within 3 months after sCRT; 5. Permitted PCI; 6. WHO PS 0-2 before sCRT. Exclusion Criteria: 1. ES-SCLC or mixed SCLC and NSCLC histology; 2. Active or prior documented autoimmune or inflammatory disorders or uncontrolled intercurrent illness; 3. Any unresolved toxicity (CTCAE Grade ≥ 2) from prior chemoradiotherapy; 4. Received concurrent chemoradiotherapy for LS-SCLC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, limited stage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, limited stage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer Hospital of Shandong First Medical University

    RECRUITING

    Jinan, China

  • Nanjing Chest Hospital

    NOT_YET_RECRUITING

    Nanjing, China

  • The First Affiliated Hospital with Nanjing Medical University

    RECRUITING

    Nanjing, China

  • The affiliated hospital of qingdao university

    RECRUITING

    Qingdao, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.